Genetron Holdings Stock – is a Buy, Sell or Hold?

0
113

The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Genetron Holdings P/E ratio is -1.8. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Genetron Holdings’s P/E ratio

What is Genetron Holdings P/E Ratio?

Genetron Holdings’ P/E ratio is -1.8, which represents a 13.21% decrease from the same period last year. their average P / E ratio is -8.51 and their 5-year average is -6.42.

What is Genetron Holdings Net EPS?

Genetron Holdings’ net earnings for the most recent quarter were -0.92$, which represents a 74.44% increase over the same period last year.

Who are Genetron Holdings Competitors?

Based on Jika.io AI model, Aspira Women’s Health, Biocartis Group NV, Biodesix, DermTech, Spectral Medical, MDxHealth SA, Personalis, Western Asset Intermediate Muni Fund are considered to be Genetron Holdings’s competitors because the companies operate within the same industry as Genetron Holdings and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Genetron Holdings.

Who is Genetron Holdings’s Biggest competitor?

Genetron Holdings’ biggest competitor is Aspira Women’s Health based on the Jika.io AI model. it has a similar market capitalization to Genetron Holdings in the industry, it dominates a similar share of the market as Genetron Holdings, and it provides and markets very similar services.

What industry is Genetron Holdings in?

Genetron Holdings is part of the Diagnostics & Research industry and the Healthcare sector.

Genetron Holdings vs Aspira Women’s Health

Market Cap: Genetron Holdings’s Market Cap of 149946816 is higher than Aspira Women’s Health Market Cap of 96499744.
Average Volume: Genetron Holdings’s Average Volume of 232254.0 is higher than Aspira Women’s Health Average Volume of 1.008M.
Beta: Genetron Holdings’s Beta of 1.25 is lower than Aspira Women’s Health Beta of 2.88.
Revenue: Genetron Holdings’s Revenue of 531.95M is lower than Aspira Women’s Health Revenue of 6.812M.
Net Income: Genetron Holdings’s Net Income of -496.238M is higher than Aspira Women’s Health Net Income of -31.662M.
Gross Profit: Genetron Holdings’s Gross Profit of 337.967M is higher than Aspira Women’s Health Gross Profit of 3.062M.
Ebitda: Genetron Holdings’s Ebitda of -490.987M is higher than Aspira Women’s Health Ebitda of -31.312M.
P/E Ratio: Genetron Holdings’s P/E Ratio of -1.8 is lower than Aspira Women’s Health P/E Ratio of -2.75.
P/S Ratio: Genetron Holdings’s P/S Ratio of 1.82 is lower than Aspira Women’s Health P/S Ratio of 13.38.
P/B Ratio: Genetron Holdings’s P/B Ratio of 0.97 is lower than Aspira Women’s Health P/B Ratio of 4.44.
P/FCF Ratio: Genetron Holdings’s P/FCF Ratio of -6.56 is higher than Aspira Women’s Health P/FCF Ratio of -2.96.
ROE: Genetron Holdings’s ROE of -0.44 is lower than Aspira Women’s Health ROE of -1.02.
ROA: Genetron Holdings’s ROA of -0.42 is lower than Aspira Women’s Health ROA of -1.13.
Return On Capital Employed: Genetron Holdings’s Return On Capital Employed of -0.55 is lower than Aspira Women’s Health Return On Capital Employed of -1.45.
Gross Profit Margin: Genetron Holdings’s Gross Profit Margin of 0.63 is higher than Aspira Women’s Health Gross Profit Margin of 0.47.
Assets (Total): Genetron Holdings’s Assets (Total) of 1.518B is lower than Aspira Women’s Health Assets (Total) of 41.079M.

Genetron Holdings vs Biocartis Group NV

Market Cap: Genetron Holdings’s Market Cap of 149946816 is higher than Biocartis Group NV Market Cap of 105653904.
Average Volume: Genetron Holdings’s Average Volume of 232254.0 is lower than Biocartis Group NV Average Volume of 66186.0.
Beta: Genetron Holdings’s Beta of 1.25 is lower than Biocartis Group NV Beta of 1.69.
Revenue: Genetron Holdings’s Revenue of 531.95M is higher than Biocartis Group NV Revenue of 48.269M.
Net Income: Genetron Holdings’s Net Income of -496.238M is lower than Biocartis Group NV Net Income of -71.472M.
Gross Profit: Genetron Holdings’s Gross Profit of 337.967M is higher than Biocartis Group NV Gross Profit of 14.347M.
Ebitda: Genetron Holdings’s Ebitda of -490.987M is lower than Biocartis Group NV Ebitda of -52.382M.
P/E Ratio: Genetron Holdings’s P/E Ratio of -1.8 is higher than Biocartis Group NV P/E Ratio of -1.71.
P/S Ratio: Genetron Holdings’s P/S Ratio of 1.82 is lower than Biocartis Group NV P/S Ratio of 2.94.
P/B Ratio: Genetron Holdings’s P/B Ratio of 0.97 is higher than Biocartis Group NV P/B Ratio of -3.04.
P/FCF Ratio: Genetron Holdings’s P/FCF Ratio of -6.56 is higher than Biocartis Group NV P/FCF Ratio of -1.89.
ROE: Genetron Holdings’s ROE of -0.44 is lower than Biocartis Group NV ROE of -4.29.
ROA: Genetron Holdings’s ROA of -0.42 is lower than Biocartis Group NV ROA of -0.42.
Return On Capital Employed: Genetron Holdings’s Return On Capital Employed of -0.55 is higher than Biocartis Group NV Return On Capital Employed of -0.49.
Gross Profit Margin: Genetron Holdings’s Gross Profit Margin of 0.63 is higher than Biocartis Group NV Gross Profit Margin of 0.43.
Assets (Total): Genetron Holdings’s Assets (Total) of 1.518B is lower than Biocartis Group NV Assets (Total) of 142.48M.

Genetron Holdings vs Biodesix

Market Cap: Genetron Holdings’s Market Cap of 149946816 is higher than Biodesix Market Cap of 61438608.
Average Volume: Genetron Holdings’s Average Volume of 232254.0 is lower than Biodesix Average Volume of 625967.0.
Beta: Genetron Holdings’s Beta of 1.25 is higher than Biodesix Beta of 0.0.
Revenue: Genetron Holdings’s Revenue of 531.95M is lower than Biodesix Revenue of 54.506M.
Net Income: Genetron Holdings’s Net Income of -496.238M is higher than Biodesix Net Income of -43.159M.
Gross Profit: Genetron Holdings’s Gross Profit of 337.967M is lower than Biodesix Gross Profit of 54.506M.
Ebitda: Genetron Holdings’s Ebitda of -490.987M is higher than Biodesix Ebitda of -44.489M.
P/E Ratio: Genetron Holdings’s P/E Ratio of -1.8 is higher than Biodesix P/E Ratio of -0.92.
P/S Ratio: Genetron Holdings’s P/S Ratio of 1.82 is lower than Biodesix P/S Ratio of 3.47.
P/B Ratio: Genetron Holdings’s P/B Ratio of 0.97 is lower than Biodesix P/B Ratio of 6.15.
P/FCF Ratio: Genetron Holdings’s P/FCF Ratio of -6.56 is higher than Biodesix P/FCF Ratio of -1.49.
ROE: Genetron Holdings’s ROE of -0.44 is lower than Biodesix ROE of -2.99.
ROA: Genetron Holdings’s ROA of -0.42 is lower than Biodesix ROA of -0.84.
Return On Capital Employed: Genetron Holdings’s Return On Capital Employed of -0.55 is lower than Biodesix Return On Capital Employed of -1.56.
Gross Profit Margin: Genetron Holdings’s Gross Profit Margin of 0.63 is lower than Biodesix Gross Profit Margin of 1.68.
Assets (Total): Genetron Holdings’s Assets (Total) of 1.518B is lower than Biodesix Assets (Total) of 76.097M.
Debt (Total): Genetron Holdings’s Debt (Total) of 73.991M is higher than Biodesix Debt (Total) of 19000.0.
Shareholders Equity: Genetron Holdings’s Shareholders Equity of 1.206B is lower than Biodesix Shareholders Equity of 19.727M.

Genetron Holdings vs DermTech

Market Cap: Genetron Holdings’s Market Cap of 149946816 is lower than DermTech Market Cap of 178445984.
Average Volume: Genetron Holdings’s Average Volume of 232254.0 is lower than DermTech Average Volume of 946496.0.
Beta: Genetron Holdings’s Beta of 1.25 is lower than DermTech Beta of 1.4.
Revenue: Genetron Holdings’s Revenue of 531.95M is higher than DermTech Revenue of 11.838M.
Net Income: Genetron Holdings’s Net Income of -496.238M is lower than DermTech Net Income of -78.335M.
Gross Profit: Genetron Holdings’s Gross Profit of 337.967M is higher than DermTech Gross Profit of 1.274M.
Ebitda: Genetron Holdings’s Ebitda of -490.987M is lower than DermTech Ebitda of -78.335M.
P/E Ratio: Genetron Holdings’s P/E Ratio of -1.8 is lower than DermTech P/E Ratio of -1.9.
P/S Ratio: Genetron Holdings’s P/S Ratio of 1.82 is lower than DermTech P/S Ratio of 25.84.
P/B Ratio: Genetron Holdings’s P/B Ratio of 0.97 is higher than DermTech P/B Ratio of 0.87.
P/FCF Ratio: Genetron Holdings’s P/FCF Ratio of -6.56 is higher than DermTech P/FCF Ratio of -3.19.
ROE: Genetron Holdings’s ROE of -0.44 is higher than DermTech ROE of -0.39.
ROA: Genetron Holdings’s ROA of -0.42 is higher than DermTech ROA of -0.39.
Return On Capital Employed: Genetron Holdings’s Return On Capital Employed of -0.55 is higher than DermTech Return On Capital Employed of -0.42.
Gross Profit Margin: Genetron Holdings’s Gross Profit Margin of 0.63 is higher than DermTech Gross Profit Margin of -0.76.
Assets (Total): Genetron Holdings’s Assets (Total) of 1.518B is lower than DermTech Assets (Total) of 248.309M.
Debt (Total): Genetron Holdings’s Debt (Total) of 73.991M is higher than DermTech Debt (Total) of 7.601M.
Shareholders Equity: Genetron Holdings’s Shareholders Equity of 1.206B is lower than DermTech Shareholders Equity of 229.698M.

About Genetron Holdings

Genetron Holdings Limited, a precision oncology company, is engaged in cancer molecular profiling and the use of molecular biology and data science for cancer treatment. the company offers diagnostic and monitoring services and early screening services through laboratory tests. it also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product for lung cancer detection; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system that detects nucleotide changes by detecting pH changes; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. in addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay for detecting hepatocellular carcinoma. furthermore, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. the company has a strategic partnership with JD Health to develop solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People’s Republic of China.

The Today Posts

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here